Helius Medical Technologies, Inc. to Present at the Benzinga Healthcare Small Cap Conference

Rhea-AI Summary

Helius Medical Technologies (HSDT) announced that CEO Dane C. Andreeff will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 1:35 PM ET. The event will be available via live webcast and archived on their website for 30 days. Helius focuses on neurological wellness and aims to develop non-invasive technologies, including its Portable Neuromodulation Stimulator (PoNS™), designed for treating gait deficits and balance issues associated with neurological conditions.

NEWTOWN, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane C. Andreeff, President and Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference as follows:

Date:	Wednesday, September 29, 2021
Time:	1:35PM ET
Webcast:	September 29 Track 2 - Livestream - Benzinga Small Cap Conference

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.heliusmedical.com, under the Investors Relations section.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com.

About the PoNS™ Device and PoNS Treatment™

The Portable Neuromodulation Stimulator (PoNS™) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS is authorized for sale in Canada for two indications: PoNS is authorized as short term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy.  PoNS is authorized for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from Multiple Sclerosis (MS) and is to be used in conjunction with physical therapy.  The PoNS™ is an investigational medical device in the Australia (“AUS”) and is currently under premarket review by the AUS Therapeutic Goods Administration.

Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

When will Helius Medical Technologies present at the Benzinga Healthcare Small Cap Conference?

Helius Medical Technologies will present on September 29, 2021, at 1:35 PM ET.

How can I watch Helius Medical Technologies' presentation at the conference?

The presentation will be available via live webcast and can be accessed through their website for 30 days after the event.

What is the focus of Helius Medical Technologies?

Helius Medical Technologies focuses on developing technologies for neurological wellness, including the PoNS™ device.

What is the Portable Neuromodulation Stimulator (PoNS™)?

PoNS™ is a non-surgical device that delivers electrical stimulation to the tongue to treat gait deficits, particularly in patients with multiple sclerosis.

What conditions does the PoNS™ device address?

The PoNS™ device treats gait deficits due to mild-to-moderate symptoms from multiple sclerosis and chronic balance deficits from traumatic brain injury.